News
The latest developments in TMS research and treatment, curated by our team.
-
Alzheimer’s researchers say brain stimulation device may slow symptoms
NBC News
In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain network that stores memories and is typically hard hit by the disease.
-
Is a brain-stimulation headset the answer to depression?
The Guardian
The makers of a device that delivers small electrical impulses to the brain are hailing the technology as a groundbreaking mental health treatment, but others are sceptical
-
rTMS depression
ScienceDirect
Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology
-
About TMS Therapy
Clinical TMS Society
Transcranial Magnetic Stimulation (TMS) is a highly effective, noninvasive, brain stimulation outpatient therapy that was cleared by the FDA for depression in 2008 and for obsessive-compulsive disorder in 2018. TMS was originally used in the 1980s for brain mapping purposes and has since been used to successfully treat many illnesses. TMS uses a high intensity magnet to focally stimulate neurons (brain cells). TMS therapy is well-tolerated and covered by most insurances.
-
“Could Accelerated TMS for Depression Become Standard?”
Psychology Today
Transcranial magnetic stimulation (TMS) was first approved for the treatment of major depressive disorder (MDD) in 2008. Because it worked well for depression by using a strong magnetic field to stimulate key brain areas, TMS was recommended early on by the American Psychiatric Association in its 2010 Practice Guidelines (APA, 2010).
-
“Cognitive” Subtype of depression may be resistant to common drugs
Technology Networks
Scientists at Stanford Medicine conducted a study describing a new category of depression — labeled the cognitive biotype — which accounts for 27% of depressed patients and is not effectively treated by commonly prescribed antidepressants.
-
UBC Scientist Dr. Fidel Vila-Rodriguez describes TMS
Capture Queue
Dr. Fidel Vila-Rodriguez is a clinical scientist at the University of British Columbia’s NINET Lab studying repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression, Parkinson’s disease, and OCD. In the second episode of the Capture Queue podcast, he explains what rTMS is, how it functions, and the work he’s doing to push for wider access to rTMS and similar treatments.
-
FDA clears NeuroStar TMS for adolescent depression treatment
Investing.com
MALVERN, Pa. – Neuronetics , Inc. (NASDAQ:STIM), a medical technology company, has received U.S. Food and Drug Administration (FDA) clearance for its NeuroStar Advanced Therapy system as an adjunct treatment for major depressive disorder (MDD) in patients aged 15-21.
-
Does ‘Brain Training’ Really Improve Cognition and Forestall Cognitive Decline?
Medscape
-
The effects of deep transcranial magnetic stimulation on Alzheimer’s disease: a case report examining cognitive functioning, memory, and QEEG
Taylor & Francis Online
-
Effects of repetitive transcranial magnetic stimulation on individual variability of resting-state functional connectivity in major depressive disorder
Journal of Psychiatry & Neuroscience
-
Depressive symptom trajectories with prolonged rTMS treatment (Blumberger and Downar)
Brain Stimulation
Evidence for extended treatment course of 35 sessions.